Phase 2 mCRPC Clinical Trials
19 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–19 of 19 trials
Recruiting
Phase 1Phase 2
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals123 enrolled19 locationsNCT07226986
Recruiting
Phase 2
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Prostate Cancer Clinical Trials Consortium126 enrolled5 locationsNCT06844383
Recruiting
Phase 1Phase 2
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Pathos AI, Inc.120 enrolled18 locationsNCT06785636
Recruiting
Phase 1Phase 2
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Arsenal Biosciences, Inc.190 enrolled9 locationsNCT07285694
Recruiting
Phase 1Phase 2
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Prostate CancerMetastatic Castration-resistant Prostate CancerUrogenital Neoplasms+3 more
Blue Earth Therapeutics Ltd82 enrolled21 locationsNCT05413850
Recruiting
Phase 2
SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC
Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Fudan University66 enrolled3 locationsNCT07451795
Recruiting
Phase 1Phase 2
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Institute of Cancer Research, United Kingdom78 enrolled4 locationsNCT07002320
Recruiting
Phase 1Phase 2
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Charles Drew University of Medicine and Science99 enrolled1 locationNCT06615752
Recruiting
Phase 1Phase 2
A Study of MHB048C in Patients With Advanced Solid Tumors
Advanced Malignant Solid TumormCRPC (Metastatic Castration-resistant Prostate Cancer)
Minghui Pharmaceutical (Hangzhou) Ltd200 enrolled1 locationNCT07192120
Recruiting
Phase 1Phase 2
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)Prostatic Neoplasms, Castration-Resistant+3 more
Celcuity Inc54 enrolled13 locationsNCT06190899
Recruiting
Phase 2
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals20 enrolled9 locationsNCT06004661
Recruiting
Phase 1Phase 2
Combination Study of Antibiotics With Enzalutamide (PROMIZE)
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Institute of Cancer Research, United Kingdom39 enrolled2 locationsNCT06126731
Recruiting
Phase 1Phase 2
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Metastatic Castration-resistant Prostate Cancer (mCRPC)Clear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals345 enrolled21 locationsNCT03972657
Recruiting
Phase 2
Dose Optimisation and Prostate-Specific Membrane Antigen (PSMA) Receptor intensification with 177Lu-PSMA Therapy: A Randomised Phase II trial: OPTIMAL-PSMA
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
St Vincent's Health Network120 enrolled1 locationACTRN12625000971437
Recruiting
Phase 2
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
Metastatic Castration-resistant Prostate Cancer (mCRPC)
MediLink Therapeutics (Suzhou) Co., Ltd.100 enrolled24 locationsNCT06241846
Recruiting
Phase 2
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Dendreon400 enrolled31 locationsNCT06134232
Recruiting
Phase 2
Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer：a Phase II Study
mCRPC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School20 enrolled1 locationNCT07093866
Recruiting
Phase 1Phase 2
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
mCRPC (Metastatic Castration-resistant Prostate Cancer)Metastatic Castrate Resistant Prostate Cancer
Evopoint Biosciences Inc.307 enrolled2 locationsNCT06702995
Recruiting
Phase 2
ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors
Metastasis Castration Resistant Prostate Cancer(mCRPC)
Hansoh BioMedical R&D Company120 enrolled15 locationsNCT06001255